JP2017519765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519765A5 JP2017519765A5 JP2016573772A JP2016573772A JP2017519765A5 JP 2017519765 A5 JP2017519765 A5 JP 2017519765A5 JP 2016573772 A JP2016573772 A JP 2016573772A JP 2016573772 A JP2016573772 A JP 2016573772A JP 2017519765 A5 JP2017519765 A5 JP 2017519765A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015093P | 2014-06-20 | 2014-06-20 | |
| US62/015,093 | 2014-06-20 | ||
| PCT/US2015/036790 WO2015196142A1 (en) | 2014-06-20 | 2015-06-19 | Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020105424A Division JP2020147609A (ja) | 2014-06-20 | 2020-06-18 | Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519765A JP2017519765A (ja) | 2017-07-20 |
| JP2017519765A5 true JP2017519765A5 (https=) | 2018-07-26 |
| JP6910800B2 JP6910800B2 (ja) | 2021-07-28 |
Family
ID=53724442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016573772A Active JP6910800B2 (ja) | 2014-06-20 | 2015-06-19 | Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 |
| JP2020105424A Pending JP2020147609A (ja) | 2014-06-20 | 2020-06-18 | Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020105424A Pending JP2020147609A (ja) | 2014-06-20 | 2020-06-18 | Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20170137505A1 (https=) |
| EP (1) | EP3157952B1 (https=) |
| JP (2) | JP6910800B2 (https=) |
| WO (1) | WO2015196142A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2791183T3 (es) | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
| ES2902533T3 (es) | 2013-11-21 | 2022-03-28 | Brigham & Womens Hospital Inc | Composiciones y métodos para tratar la hipertensión pulmonar |
| EP3174550B1 (en) * | 2014-08-01 | 2020-01-29 | The Brigham and Women's Hospital, Inc. | Methods and compositions relating to treatment of pulmonary arterial hypertension |
| WO2017189724A1 (en) | 2016-04-27 | 2017-11-02 | Novartis Ag | Antibodies against growth differentiation factor 15 and uses thereof |
| KR20190059312A (ko) * | 2016-10-12 | 2019-05-30 | 얀센 바이오테크 인코포레이티드 | Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법 |
| CN112912395B (zh) | 2018-08-20 | 2024-08-23 | 辉瑞公司 | 抗gdf15抗体、组合物和使用方法 |
| JP2024541933A (ja) | 2021-11-02 | 2024-11-13 | ファイザー・インク | 抗ｇｄｆ１５抗体を使用してミトコンドリア筋症を処置する方法 |
| CN120098108A (zh) * | 2025-03-11 | 2025-06-06 | 哈尔滨医科大学 | 人重组gdf15蛋白及其在制备防治脓毒症急性肾损伤的药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5733254A (en) | 1987-10-15 | 1998-03-31 | Cypress Bioscience, Inc. | Method for treating patients suffering from immune thrombocytopenic purpura |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
| WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| CA2390820A1 (en) * | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| EP2441466B1 (en) * | 2004-04-13 | 2014-07-23 | St Vincent's Hospital Sydney Limited | MIC-1 inhibiting agent |
| MX2009000914A (es) * | 2006-08-04 | 2009-06-18 | Hannover Med Hochschule | Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento. |
| US20100278843A1 (en) * | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
| CN101896192A (zh) * | 2007-10-09 | 2010-11-24 | 圣文森特医院悉尼有限公司 | 一种通过去除或灭活巨噬细胞抑制因子-1而治疗恶病质的方法 |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| ES2791183T3 (es) * | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
-
2015
- 2015-06-19 JP JP2016573772A patent/JP6910800B2/ja active Active
- 2015-06-19 EP EP15742142.1A patent/EP3157952B1/en active Active
- 2015-06-19 WO PCT/US2015/036790 patent/WO2015196142A1/en not_active Ceased
- 2015-06-19 US US15/320,094 patent/US20170137505A1/en not_active Abandoned
-
2018
- 2018-11-01 US US16/177,792 patent/US20190292251A1/en not_active Abandoned
-
2020
- 2020-06-18 JP JP2020105424A patent/JP2020147609A/ja active Pending
-
2022
- 2022-02-02 US US17/649,732 patent/US20220403015A1/en active Pending